

Haematologica  
HAEMATOL/2018/192807  
Version 4

Antitumor synergy with SY-1425, a selective RAR $\alpha$  agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia

Michael R. McKeown, Liv Johannessen, Emily Lee, Christopher Fiore, and Emmanuelle di Tomaso

Disclosures: All work was funded by Syros Pharmaceuticals. All authors were employees of Syros Pharmaceuticals when the work was performed. One unpublished PCT application filed in 2017 One unpublished PCT application filed in 2018

Contributions: Michael McKeown: Designed the research study, Performed data analysis, Critically reviewed the manuscript, Approved final draft of manuscript Liv Johannessen: Performed data analysis, designed experiments, Critically reviewed the manuscript, Approved final draft of manuscript Emily Lee: Performed data analysis, Approved final draft of manuscript Chris Fiore: Performed data analysis, Approved final draft of manuscript Emmanuelle di Tomaso: Designed the research study, Critically reviewed the manuscript, Approved final draft of manuscript